Generali Investments CEE investicni spolecnost a.s. Takes Position in CVS Health Co. (NYSE:CVS)

Generali Investments CEE investicni spolecnost a.s. bought a new position in shares of CVS Health Co. (NYSE:CVS - Free Report) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm bought 11,500 shares of the pharmacy operator's stock, valued at approximately $516,000.

Several other hedge funds have also recently bought and sold shares of CVS. State Street Corp raised its holdings in shares of CVS Health by 3.6% in the third quarter. State Street Corp now owns 56,527,909 shares of the pharmacy operator's stock valued at $3,554,475,000 after purchasing an additional 1,989,066 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of CVS Health by 1.8% in the third quarter. Geode Capital Management LLC now owns 26,361,673 shares of the pharmacy operator's stock valued at $1,651,997,000 after purchasing an additional 461,569 shares during the last quarter. Pzena Investment Management LLC raised its holdings in shares of CVS Health by 1.5% in the third quarter. Pzena Investment Management LLC now owns 13,135,308 shares of the pharmacy operator's stock valued at $825,948,000 after purchasing an additional 198,920 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of CVS Health by 5.8% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 12,918,949 shares of the pharmacy operator's stock valued at $579,932,000 after purchasing an additional 710,281 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC raised its holdings in shares of CVS Health by 34.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 11,897,034 shares of the pharmacy operator's stock valued at $748,085,000 after purchasing an additional 3,071,613 shares during the last quarter. 80.66% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

CVS Health Stock Performance

Shares of CVS Health stock traded up $1.09 during trading on Friday, reaching $66.34. The company's stock had a trading volume of 10,082,148 shares, compared to its average volume of 11,965,158. The business's 50-day moving average price is $56.42 and its 200-day moving average price is $56.73. The firm has a market cap of $83.64 billion, a PE ratio of 18.12, a P/E/G ratio of 0.98 and a beta of 0.54. CVS Health Co. has a 52 week low of $43.56 and a 52 week high of $80.75. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS - Get Free Report) last posted its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. Equities analysts forecast that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Investors of record on Thursday, January 23rd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 23rd. This represents a $2.66 annualized dividend and a yield of 4.01%. CVS Health's dividend payout ratio is 72.68%.

Wall Street Analysts Forecast Growth

CVS has been the topic of a number of recent research reports. Wells Fargo & Company lifted their price objective on shares of CVS Health from $68.00 to $73.00 and gave the company an "overweight" rating in a report on Thursday, February 13th. Evercore ISI boosted their target price on shares of CVS Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a report on Monday, January 27th. UBS Group lowered their target price on shares of CVS Health from $62.00 to $59.00 and set a "neutral" rating on the stock in a report on Tuesday, February 11th. StockNews.com upgraded shares of CVS Health from a "sell" rating to a "hold" rating in a report on Thursday, February 13th. Finally, Barclays boosted their target price on shares of CVS Health from $71.00 to $73.00 and gave the stock an "overweight" rating in a report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $69.83.

Insider Buying and Selling

In other CVS Health news, Director Michael F. Mahoney bought 30,000 shares of the stock in a transaction on Tuesday, February 18th. The stock was purchased at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the purchase, the director now owns 39,356 shares in the company, valued at $2,625,045.20. The trade was a 320.65 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, SVP James David Clark sold 7,513 shares of the business's stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the transaction, the senior vice president now directly owns 8,394 shares of the company's stock, valued at approximately $556,941.90. The trade was a 47.23 % decrease in their position. The disclosure for this sale can be found here. 0.24% of the stock is currently owned by company insiders.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.